medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2018, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2018; 63 (2)

Clostridium difficile colitis during tuberculosis treatment

Shveid GD, Canales ASJ, Muñoz BJM, Moreno SF

Language: Spanish
References: 9
Page: 122-124
PDF size: 167.08 Kb.


ABSTRACT

It is well known that within the treatment for tuberculosis, rifampicin is the antibiotic that changes the intestinal microbiome the most, but it is not recognized as one of the most frequent causative antibiotics of Clostridium difficile infection, such as cephalosporins and clindamycin. This is why there is a constant debate regarding whether or not to suspend the Tb medications in patients with Clostridium difficile colitis. Regarding the development of resistant strains, there are few tests, like the Etest strips, that confirm their presence; we are in need of newer tests to assess these findings. We present the case of an 83-year-old female who came to the clinic because of a three-week-long case of abdominal pain and diarrhea without dysenteric characteristics. Her medical history included Parkinson’s disease, atrial fibrillation and hypertension. Three months before her current condition, she was diagnosed with pleural tuberculosis, and was treated with surgical decortication and Tb antibiotics, including rifampicin. The purpose of this case report is to analyze the relationship between rifampicin and infection by Clostridium difficile, and the effect that rifamycins may have in the development of resistant strains.


REFERENCES

  1. Sun YX, Zhao YT, Teng LL, Jiang H, Shao L. Clostridium difficile infection associated with antituberculous agents in a patient with tuberculous pericarditis. Intern Medic. 2013; 52 (13): 1495-1497.

  2. Fekety R, O’Connor R, Silva J. Rifampin and pseudomembranous colitis. Rev Infect Dis. 1983; 5 (Suppl 3): S524-527.

  3. Curry S, Marsh J, Shutt K, Muto C, O’Leary M, Saul M et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009; 48 (4): 425-429.

  4. Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile Strains in Canada and Italy and predictive accuracy of rifampin etest for rifamycin resistance. J Clin Microbiol. 2011; 49 (12): 4319-4321.

  5. Lee YM, Huh KC, Yoon SM, Jang BI, Shin JE, Koo HS et al. Incidence and clinical outcomes of Clostridium difficile infection after treatment with tuberculosis medication. Gut Liver. 2016; 10 (2): 250-254.

  6. O’Connor JR, Galang MA, Sambol SP, Hecht DW, Vedanta G, Gerding DN et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008; 52 (8): 2813-2817.

  7. Tenover FC, Tickler IA, Persing DH. Antimicrobial-resistant strains of Clostridium difficile form North America. Antimicrobial Agents Chemother. 2012; 56 (6): 2929-2932.

  8. Kullin B, Wojno J, Abratt V, Reid SJ. Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa. Eur J Clin Microb Infect Dis. 2017; 36 (1): 163-175.

  9. Dang U, Zamora I, Hevener K, Adhikari S, Wu X, Hurdle J. Rifamycin resistance in Clostridium difficile is generally associated with a low fitness burden. Antimicrob Agents Chemother. 2016; 60 (9): 5604-5607.




2020     |     www.medigraphic.com